Second-generation anti-androgens, including Enzalutamide and Abiraterone, are primary therapeutic agents that function by inhibiting AR activity, thereby arresting cell cycle progression and triggering signaling pathways that culminate in PCa cell death23. Here, AR is linked to posterior cortical atrophy.